Currently, there are 81.59M common shares owned by the public and among those 27.25M shares have been available to trade.
The company’s stock has a 5-day price change of -2.54% and 22.32% over the past three months. MNMD shares are trading 99.18% year to date (YTD), with the 12-month market performance up to 102.50% higher. It has a 12-month low price of $3.49 and touched a high of $12.22 over the same period. MNMD has an average intraday trading volume of 1.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.59%, 2.31%, and -4.33% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Mind Medicine Inc (NASDAQ: MNMD) 81.59M shares outstanding.
It has a market capitalization of $534.59M and a beta (3y monthly) value of 1.70. The earnings-per-share (ttm) stands at -$2.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.02% over the week and 7.23% over the month.
Earnings per share for the fiscal year are expected to increase by 40.57%, and 0.48% over the next financial year.
Looking at the support for the MNMD, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on December 20, 2024, with the firm’s price target at $20. Leerink Partners coverage for the Mind Medicine Inc (MNMD) stock in a research note released on October 14, 2024 offered a Outperform rating with a price target of $20. ROTH MKM was of a view on July 24, 2024 that the stock is Buy, while Robert W. Baird gave the stock Outperform rating on May 29, 2024, issuing a price target of $27. Leerink Partners on their part issued Outperform rating on April 15, 2024.
